1. Home
  2. CFND vs CUE Comparison

CFND vs CUE Comparison

Compare CFND & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$3.82

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$0.31

Market Cap

27.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CFND
CUE
Founded
N/A
2014
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
27.1M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
CFND
CUE
Price
$3.82
$0.31
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.00
AVG Volume (30 Days)
24.8K
316.8K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
35.14
EPS
N/A
N/A
Revenue
N/A
$9,287,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
69.16
52 Week Low
$3.68
$0.23
52 Week High
$9.67
$1.12

Technical Indicators

Market Signals
Indicator
CFND
CUE
Relative Strength Index (RSI) 44.45 47.64
Support Level $3.82 $0.29
Resistance Level $4.08 $0.36
Average True Range (ATR) 0.16 0.02
MACD 0.03 0.00
Stochastic Oscillator 70.00 73.35

Price Performance

Historical Comparison
CFND
CUE

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: